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Background: In African American (AA) men, central BP may better reflect the levels of vascular burden than peripheral (brachial) BP. There is 
a paucity of data on the efficacy of antihypertensive agents on central pressure in AA. This 8-week prospective, multicenter, randomized, double-
blind study of AA patients with stage 2 (MSSBP ≥ 160 mmHg and < 200 mmHg) hypertension evaluated the brachial and central BP responses of 
treatment with the single pill combination aliskiren/HCTZ (A/H) compared with amlodipine (AML).
Methods: Following a 1-4 week washout eligible patients ≥18 years (mean age= 52.6), received either A/H150/12.5 mg (n=166) or AML 5 mg 
(n=166) for 1 week; force titrated to A/H 300/25 or AML 10 mg for 7 weeks. Primary efficacy was change from baseline in MSSBP at Week 8. A 
substudy (n=52) evaluated treatment differences in central BP.
Results: At week 8, both treatments provided significant reductions in MSSBP from baseline [-28.6 ±17.95, -28.2 ± 13.17 mm Hg] in the A/H 
and AML arms, with no significant differences between treatments. However, A/H significantly reduced (p <0.05) central SBP and increased pulse 
pressure amplification ratio (brachial/central) vs AML (Table). Both treatments were well tolerated.
Conclusion: Despite similar reductions in peripheral SBP with the 2 treatments, reductions in central systolic pressure was significantly in favor of 
A/H. Our findings suggest an important new treatment option since central pressure is considered an important risk factor in AA patients.
Parameters
Aliskiren/HCTZ§
(N, ITT = 162)
AML§
(N, ITT = 162)
Aliskiren/HCTZ vs. AML
LS mean difference 
[95% CI]
Baseline Week 8
Change from 
baseline, LS 
Mean
Baseline Week 8
Change from 
baseline, LS 
Mean
MSSBP mmHg 168.2 ± 8.5 138.8±18.2 -28.61 168.1 ± 8.0 139.1 ± 14.5 -28.18 -0.42 [-3.8, 2.9]
MSDBP, mmHg 96.0 ± 9.8 86.0 ± 12.0 -9.41 95.0 ± 8.9 84.0 ± 9.7 -10.89 1.48 [-0.63, 3.59]
MSPP, mmHg 72.2 ± 12.1 52.7 ± 14.9 -19.16 73.1 ± 11.6 55.1 ± 12.1 -17.31 -1.85 [-4.39, 0.69]
Central SBP 153.9 ± 10.8 123.0 ± 12.1 -30.13 153.2 ± 10.5 132.3 ± 11.6 -21.22 -8.91* [-16.9, -0.87]
Central DBP 96.8 ±10.5 84.9 ± 11.7 -11.03 95.2 ± 8.9 87.8 ± 7.7 -7.03 -4.0 [-9.42, -1.41]
Central PP 57.3 ± 15.9 38.2 ± 13.6 -19.06 58.0 ± 12.5 44.5 ± 12.0 -14.20 -4.86 [-11.2, -1.49]
PP amplification ratio 1.28 ± 0.19 1.35 ± 0.17 0.126 1.28 ± 0.2 1.25 ± 0.17 0.02 0.11* [0.01, 0.2]
§ for central pressure data n= 27 in Aliskiren/HCTZ and n= 25 in Aml group. Data are mean ± SD. ITT = intent-to-treat
MSSBP = Mean sitting systolic BP, MSDBP = Mean sitting diastolic BP and MSPP = Mean sitting pulse pressure*p <0.05; PP amplification ratio = 
peripheral PP/central PP
